Market Overview

The Global Veterinary Health Products Market was valued at USD 12.87 billion in 2024 and is projected to reach USD 33.45 billion by 2034, growing at a CAGR of 6.5% during the forecast period 2025-2034.

Global Veterinary Health Products Market is not available in terms of revenue from the public sources, but it has a growing role from government programs, government organizations and regulation for health promotion. In India, the Department of Agricultural Research and Education (DARE) under the Ministry of Agriculture runs several central schemes. The Indian Council of Agricultural Research (ICAR) has the scheme called “Animal Health Management and Veterinary Education” that covers disease surveillance, vaccine creation and preventative health care. This shows that the government has programs for better veterinary care and services. In the United States, the Food and Drug Administration (FDA) supports the health market. The FDA has a centre called the Centre for Veterinary Medicine (CVM). It keeps watch on the safety of drugs, food and devices used on animals. The FDA finds out about and acts against problems with drugs and food for animals. It also gets reports of bad effects that drugs or food might cause. This helps the FDA keep control of the veterinary health market.

In the United Kingdom, the Competition and Markets Authority (CMA) started looking into the veterinary health sector because it had questions about how much the vets were charging. This was also done to investigate how the market is getting smaller. This shows that the government is keeping a close eye on how much veterinary drugs and services cost. Their goal is to keep vets and pet owners safe. We do not have figures on the size of the market from these government bodies, but their work shows that they are now more active in making sure animals get good health care.

This changing system of regulation and rules shows that the market for veterinary health products is moving in a good direction. There are many reasons for this. The most important reasons are that the products must be safe, easy to find and cheap.

Market Drivers

Public investment and regulatory frameworks accelerating veterinary healthcare adoption

• Public expenditure and legislation are the major stimuli that drive the demand for veterinary health product. In India, an NFDA for Foot and Mouth Disease (FMD) and Brucellosis (two of the three `target` diseases for the EU`s control policy) is already at practice through the National Animal Disease Control Program (NADCP). The programme is fully funded to 2024 by the central government, it said, and aims to end these diseases by 2030, raising demand for veterinary vaccines and diagnostics. India also possesses an extensive network of veterinary infrastructure, such as 22 868 dispensaries, 33 383 aid centres and 13 085 veterinary hospitals, which contribute to disease surveillance and livestock outreach. In the U.S., the Food and Drug Administration’s Centre for Veterinary Medicine (FDA CVM) has authority over veterinary drugs, biologics and feed. Its responsibilities comprise pre-market clearance, post-market surveillance, adverse event report and antimicrobial stewardship to re-enforce safety and efficacy measures throughout the industry. In the UK, such regulatory roles are undertaken by the Veterinary Medicines Directorate (VMD) in DEFRA. Together, these national frameworks provide overall widespread institutional support for the development and oversight of veterinary health products.

Market Opportunity

Disease control programs and government-supported research enabling innovation and product uptake

• supported disease control policy and veterinary research development are establishing favourable conditions for market growth. Products for use in livestock are in demand in India, particularly vaccines, dewormers, feed additives, and diagnostic kits as part of the DAHD and ICAR programs aimed at improving livestock productivity and disease resistance, dairy, and poultry. Public–private partnerships in such programmes create an environment where the private sector can co-develop solutions that will be piloted (demonstrate) in government-sponsored demonstration projects. The USDA National Animal Health Monitoring System (NAHMS) in the United States offers national epidemiological data for development of preventive health plans, influencing supply planning and use of veterinary pharmaceuticals. Meanwhile, global movements in antibiotic stewardship and animal welfare have encouraged government investment in research on biologics, probiotics, and immune-modulating agents. These are creating opportunities for private-sector companies to partner with the public sector and access co-funded grants, testing, and preferred-procurement status in the context of national programs, for innovative veterinary therapeutics and vaccines.

Market Restraining Factor

Lack of standardized data, infrastructure limitations, and regulatory compliance burdens

• this industry has some support amongst institutions, but there are a few things preventing it from taking off. One of the most apparent constraints is that there is no transparency on public revenue and market size, hence an official market metric is discouraged. Variability in infrastructure among regions, particularly in rural or resource limited areas, contributes to differential availability of veterinary care and product distribution. In India there are many outlets, but issues in logistics and staff levels restrict regular availability of essential products for veterinary medicines. You can look for peace of mind knowing that not all of these devices get through the FDA CVM, which is great– we would barely be able to keep up with the competition if they let just anyone in! In the U.S. and other possibly over-regulated markets, there can be a difficult, expensive approval and vetting procedure that turns many a small and medium mom-and-pop shop away. Additionally, post-marketing surveillance and reporting requirements add to the cost burden of compliance, particularly for new or high-risk categories like anti-microbials and biotech. These barriers will also likely limit uptake, in particular in existing systems and low-resource settings, unless additional investment and harmonisation of product registration and distribution occurs.

Segmentation Analysis

By Product Type

The veterinary health product market is broad, encompassing all types of products intended to maintain animal health, improve animal productivity, and prevent disease. The pharmaceutical class is the most important group; antiparasitic, anti-infectives, anti-inflammatory and anaesthetics for companion and livestock animals fall in this category. Vaccines is yet another important category, categorizing viral/bacterial and combination vaccines administered primarily as a preventive of diseases like Foot and Mouth Disease, rabies and Brucellosis. Dietary supplements as vitamins, minerals and amino acids are broadly utilized to enhance immune function and performance in animals particularly in poultry and dairy field. Virus and antibody diagnostic reagents, including rapid tests and lab kits, allowing early detection and helping prevent for severe complications. Topical preparations, wound care products, and dermatological products are also widely used in both human and animal medicine.

By Animal Type

Classifications of veterinary health products are in relation to target animal species. Cattle, poultry, swine, sheep, and goats are the leading segment, assisted by soaring world meat, milk, and eggs consumption. Vaccination, deworming, and growth promotion practices are widely implemented among these animals to achieve productivity and avoid outbreaks in a large scale. The companion animals such as dogs and cats is a growing market owing to pet ownership as well as increase in the knowledge of pet health. Vaccines, flea and tick products, dermatology products, and pain management products all fall under this category. Horse care products cater to a smaller, yet niche category such as the performance horse, in which nutritional and orthopaedic products are marketed well.

By Route of Administration

The animals receiving veterinary health products are receiving them through multiple routes based on the species and intent. The oral administration as tablets, boluses, premixes, or feed additives is routinely the most common in practice, being cost effective, quick and easy for mass treatment of large herds or flocks. Injectable medications, such as vaccines and antibiotics, are rapidly absorbed and doses accurately, they are appropriate for emergencies. You will apply topical products to rinse for parasites or heal wounds. Intra-mammary, intra-uterine and pour-on formulations are also used for livestock management, particularly, with dairy cattle for mastitis treatment and reproductive purposes.

By Distribution Channel

The veterinary health product's distribution is also regulated through many channels for wide availability. Veterinary clinics and hospitals are an important sales channel, especially for Rx and specialized diagnostics. They supply walk-in customers from retail pharmacies and veterinary drug stores (including pet owners and small holders). Over the counter (OTC) veterinary products are rapidly gaining momentum on e-commerce, particularly in urban areas with higher penetration of digital. Public sector supply chains (e.g., national livestock programs) are pivotal for mass vaccination campaigns and for the distribution of subsidized medicine in developing countries.

By End User

Veterinary health products find utility in the hands of different end users according to their abilities and professions. Veterinary professionals, including registered veterinarians and para-vets, are the main users responsible for the diagnoses, prescriptions, and treatment of sick animals, both livestock and companion. Livestock farmers and poultry producers are also important end users, employing these vaccines, feed supplements, and preventive medicines against herd-level health management. Pet owners are key end users in the companion animal segment of veterinary health products since they purchase both over the counter and prescription products for the day-to-day care of their pets. This end-user category also includes government agencies and public health programs that undertake mass immunization and disease eradication campaigns, using huge volumes of veterinary health products.

Regional Snapshot

North America

• For veterinary health products, North America is a mature and well-regulated market, characterized by strong institutional oversight and high awareness of animal healthcare among stakeholders. FDA CVM centre for veterinary medicine-United States Government ensures that drug, vaccine, and feed additive products for animal health are stringently regulated, establishing confidence and trust in these products, especially in the companion and livestock sectors. Programs within the auspices of the U.S. Department of Agriculture, such as those under the National Animal Health Monitoring System (NAHMS), provide essential epidemiological data for guiding trends in the development and use of veterinary products. Furthermore, public investment helps to support disease control programs such as eradication and vaccination campaigns concerning zoonotic and livestock diseases. It is CFIA (the Canadian Food Inspection Agency) that is responsible for the approval of veterinary drugs in Canada, as well as for coordinating programs related to animal health monitoring. Coordination with provinces is via targeted funding relating to infrastructure in veterinary services to ensure effective vaccine distribution for certain health surveillance programs of livestock.

Europe

• Policy frameworks for veterinary products across countries in Europe maintain far-reaching authorities and regulations which include the European Medicines Authority and the concerned national authorities. The Veterinary Medicinal Products Regulation of the European Union (Regulation (EU) 2019/6), in place since 2022, harmonizes rules across member states, making traceability and pharmacovigilance more effective. Other stakeholders in the fight against antimicrobial resistance (AMR) such as Germany, France, and the Netherlands promote the use of vaccines, probiotics, and alternative non-antibiotic treatments as part of AMR strategies actively funded by their national governments. By improving surveillance and early-warning systems, government-run animal health can be integrated within a structured framework for the distribution of veterinary products. Frequently, public procurement guidelines in Europe focus on the responsible use of antimicrobials and support innovative biologics and diagnostics in both livestock and companion animal sectors.

Asia Pacific

• These regions of the Asia Pacific are experiencing increased business in the veterinary products, arising from large livestock populations, expanding commercial farming, and increasingly keeping pets. The Department of Animal Husbandry and Dairying (DAHD) in India is supervising the conduct of several centrally funded programs, which include the National Animal Disease Control Program (NADCP), a mass vaccination program against Foot and Mouth Disease (FMD), and Brucellosis. Furthermore, ICAR helps veterinary research in national institutes to develop vaccines and innovate veterinary diagnostics in India. China, Japan, and South Korea set strict veterinary drug regulations by governments and support advanced disease surveillance programs. Countries in the Southeast Asia region engage in public–private partnerships with FAO and OIE to control transboundary animal diseases and improve access to essential veterinary medicines.

Latin America

• Zealously devoting efforts in veterinary health in Latin America to livestock productivity, zoonoses, and export regulations, Brazil's Ministry of Agriculture, Livestock, and Food Supply (MAPA) is involved in regulating veterinary products and running major FMD and brucellosis control programs. Like the case are Argentina, Chile, and Mexico-all of which have national animal health services to regulate the use of veterinary medicines and to promote livestock vaccination campaigns. Public veterinary services usually work closely with regional development organizations in providing subsidized or free access to vaccines and anthelmintics in the most rural and economically disadvantaged areas. Regional governments are promoting traceability and pharmacovigilance systems to enable regional compliance with international trade and safety standards.

Middle East & Africa

• There is an expansion of veterinary health infrastructures across the Middle East and Africa to enhance the growing importance of livestock in food security and rural livelihood. Countries such as Saudi Arabia and the UAE are investing in veterinary services as part of national food sustainability programs. These include public procurement of vaccines and diagnostic tools for camels, poultry, and dairy cattle. On the other hand, the African Union's Inter-African Bureau for Animal Resources (AU-IBAR) collaborates with national ministries in enhancing veterinary services to include disease surveillance, vaccination coverage, and development of veterinary workforce. This is because countries such as Kenya, Ethiopia and Nigeria have initiated government programs targeting control of endemic livestock diseases with support from multilateral such as the World Bank and the FAO. Despite this challenge related to funding and infrastructure; public sector initiatives are fuelling increased national demand for affordable and accessible veterinary health products throughout the region.

List of Top Leadinh Companies

• Zoetis Inc.
• Boehringer Ingelheim International GmbH
• Merck Animal Health (MSD Animal Health)
• Elanco Animal Health Incorporated
• Ceva Santé Animale
• Vetoquinol S.A.
• Virbac
• Bayer Animal Health (now part of Elanco)
• Dechra Pharmaceuticals PLC
• IDEXX Laboratories, Inc.
• Phibro Animal Health Corporation
• Bimeda Holdings PLC
• Norbrook Laboratories Ltd.
• Neogen Corporation
• Orion Animal Health (part of Orion Corporation)

The Key developments

July 2025: Bravecto Quantum (fluralaner extended-release injectable suspension) is approved by the U.S. FDA for dogs and puppies, who are 6 months to over. This is the first drug ranging between 8 to 12 months of protection from fleas and ticks in dogs.

July 2025: Bringing the FDA first to approve Exzolt (fluralaner oral solution) for Kytori mite treatment in laying hens and replacement chickens, this is the first oral and FDA separately registered product specificity.

March 2024: FDA approved the first otic non-antibiotic treatment against yeast ear infections in dogsTerbinafine, with betamethasone acetate (trade name: Duotic), was approved by the Centre for Veterinary Medicine of the U.S.-FDA in March 2024. It is the first ear gel approved by FDA for yeast-only caused otitis in dogs that does not contain an antibiotic

September 2024: FDA approved a new JAK inhibitor for allergic skin conditions in dogsapproved by the FDA CVM in September 2024. Ilunocitinib (trade name Zenrelia) was for the control of skin itchiness and atopic dermatitis in dogs. In June 2025, it received a positive opinion from the European Medicines Agency CVMP.

November 2024: FDA approves generic firsts for florfenicol-the disease in freshwater-reared fish Paqflor is a florfenicol generic approved by FDA CVM in November 2024 for management of furunculosis, coldwater disease, columnaris disease, and septicemia in numerous species of freshwater fish.

February April 2024: FDA announces multiple approvals and guidance’s for new animal other approvals were announced by FDA CVM between February and April 2024: This is the first tissue-based product for dogs; first generic for congestive heart failure in dogs to be approved: pimobendan; new antimicrobial for cattle and swine. The agency finalized new guidance on Veterinary Feed Directives.  

October 2024: FDA restructures office for evaluating originator and generic animal drugs separately. This improvement of the regulatory clarity and review processes started October 20, 2024, when FDA CVM reorganized its Office of New Animal Drug Evaluation into a different office for the originator product and a different one for the generic product.

Report Coverage

The report will cover the qualitative and quantitative data on the global veterinary health products market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations: